DVAX Dynavax Technologies Corporation

4.21
+0.12  (+3%)
Previous Close 4.09
Open 4.08
Price To Book 32.38
Market Cap 352,291,659
Shares 83,679,729
Volume 791,287
Short Ratio
Av. Daily Volume 1,572,834
Stock charts supplied by TradingView

NewsSee all news

  1. Dynavax to Present at the 2019 Cantor Global Healthcare Conference

    BERKELEY, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX), today announced that Ryan Spencer, Senior Vice President, Commercial, and Interim Co-President, will present at the

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Announced May 23, 2019 that it will discontinue investment in this program.
SD-101 + Pembrolizumab
Melanoma and head and neck squamous cell carcinoma (HNSCC)
CRL February 25, 2013 and November 14, 2016. Advisory Committee Meeting July 28, 2017 voted 21 -1 in favor of recommending approval. Final approval announced November 9, 2017.
HEPLISAV-B
Hepatitis B
Phase 2a trial did not meet primary endpoint - November 29, 2018.
AZD1419
Asthma
Announced May 23, 2019 that it will discontinue investment in this program.
DV281
Non-small Cell Lung Cancer (NSCLC)
Phase 1 commencement of enrolment announced May 2, 2019.
HEPLISAV-B
End Stage Renal Disease on Dialysis

Latest News

  1. Dynavax to Present at the 2019 Cantor Global Healthcare Conference

    BERKELEY, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX), today announced that Ryan Spencer, Senior Vice President, Commercial, and Interim Co-President, will present at the